{
    "clinical_study": {
        "@rank": "93930", 
        "arm_group": [
            {
                "arm_group_label": "INCB024360", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects randomized to Arm A (INCB024360) will take INCB024360 tablets at a dose of 600 mg BID, beginning on Day 1."
            }, 
            {
                "arm_group_label": "Tamoxifen", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects randomized to Arm B (tamoxifen) will take tamoxifen tablets at a dose of 20 mg BID, beginning on Day 1."
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, randomized, phase 2 study of an IDO inhibitor, INCB024360 versus\n      tamoxifen in biochemical recurrent only ovarian cancer patients following complete remission\n      with first-line chemotherapy."
        }, 
        "brief_title": "A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Biochemical-recurrent Only Epithelial Ovarian Cancer", 
            "Primary Peritoneal Carcinoma", 
            "Fallopian Tube Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Ovarian Neoplasms", 
                "Fallopian Tube Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have received first-line chemotherapy, which must have been a\n             platinum-containing regimen.\n\n          -  Subjects who received maintenance paclitaxel or, bevacizumab, or alternative\n             maintenance therapy (e.g. vaccines) are eligible for enrollment provided they have\n             discontinued therapy at least 4 weeks for prior taxane and, at least 8 weeks for\n             bevacizumab, or received medical monitor approval for time lapse from alternative\n             maintenance therapy prior to randomization and recovered from toxicities to less than\n             Grade 2.\n\n          -  Subject must be currently in remission by clinical and radiological criteria\n             (Response Evaluation Criteria for Solid Tumors [RECIST 1.1]).\n\n             a. If a PET scan or high-resolution CT scan is performed and   demonstrates new\n             disease </= 1 cm, these subjects would be eligible.\n\n          -  Clinical remission is defined as: asymptomatic and a negative physical examination.\n\n          -  Scans are required post completion of platinum-containing therapy to document disease\n             remission.\n\n          -  Prior to the first-line regimen, CA 125 must have been elevated at first diagnosis,\n             must have normalized with the first-line therapy/regimen, and is currently elevated:\n\n             a. CA 125 elevation is defined as 2 consecutive measurements that are both above the\n             Upper Limit of Normal (ULN) at least 42 weeks apart, with the second measure showing\n             further increases from the first measurement\n\n               1. If CA 125 is \u2265 2 \u00d7 ULN the confirmatory value only needs to be 1 week apart.\n\n               2. CA 125 elevation is defined as a value that is at least 2 \u00d7 ULN on 2 occasions\n                  at least 1 week apart (UK ONLY REQUIREMENT).\n\n          -  CA 125 elevation must be at least 3 months from completion of first-line\n             platinum-containing regimen.\n\n          -  Documentation of at least 1 normal CA 125 level at approximately 3 months during or\n             following first line therapy is required.\n\n          -  Subjects must have available archived tumor tissue.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\n          -  Adequate renal, hepatic, and bone marrow function based on screening laboratory\n             assessments.\n\n        Exclusion Criteria:\n\n          -  Subjects with any evidence of new disease (> 1 cm) including new ascites as confirmed\n             by imaging.\n\n          -  Any other prior antitumor systemic therapy except for first-line chemotherapy\n             associated with previous CA 125 normalization or maintenance paclitaxel, bevacizumab,\n             or alternative maintenance therapy as approved by the medical monitor.\n\n          -  Subjects with prior radiotherapy within 3 months of randomization and have not\n             recovered from all radiotherapy-related toxicities, who have received radiation\n             therapy to the chest within 3 months of randomization, or who have a history or\n             radiation pneumonitis.\n\n          -  Subjects with protocol-specified active autoimmune processes except vitiligo or\n             thyroiditis.\n\n          -  Subjects receiving investigational study drug for any indication, immunological-based\n             treatment for any reason(except completed adjuvant therapy with medical monitor\n             approval), or potent CYP3A4 inducers or inhibitors.\n\n          -  Subjects receiving monoamine oxidase inhibitors (MAOIs) within the 21 days prior to\n             screening; subjects who have ever had Serotonin Syndrome (SS) after receiving 1 or\n             more serotonergic drugs.\n\n          -  Subjects for whom tamoxifen therapy is contraindicated."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "110", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01685255", 
            "org_study_id": "INCB 24360-210"
        }, 
        "intervention": [
            {
                "arm_group_label": "INCB024360", 
                "intervention_name": "INCB024360", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tamoxifen", 
                "intervention_name": "tamoxifen", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tamoxifen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "FIGO Stage III or IV EOC", 
            "PPC FTC", 
            "increasing CA 125"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Evanston", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Joilet", 
                        "country": "United States", 
                        "state": "Illinois"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Covington", 
                        "country": "United States", 
                        "state": "Louisiana"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bridgewater", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mineola", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Abington", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bendigo", 
                        "country": "Australia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Australia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Herston", 
                        "country": "Australia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milton", 
                        "country": "Australia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Randwick", 
                        "country": "Australia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ekaterinburg", 
                        "country": "Russian Federation"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izhevsk", 
                        "country": "Russian Federation"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krasnodar", 
                        "country": "Russian Federation"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kursk", 
                        "country": "Russian Federation"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orenburg", 
                        "country": "Russian Federation"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "Russian Federation"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ufa", 
                        "country": "Russian Federation"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chernivtsi", 
                        "country": "Ukraine"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dnepropetrovsk", 
                        "country": "Ukraine"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lutsk", 
                        "country": "Ukraine"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bebington", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cardiff", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Keighley", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liverpool", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oxford", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Midlands", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Canada", 
                "Russian Federation", 
                "Ukraine", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy", 
        "overall_contact": {
            "last_name": "Incyte Corporation Call Center", 
            "phone": "1.855.463.3463"
        }, 
        "overall_official": {
            "affiliation": "Incyte Corporation", 
            "last_name": "Lance Leopold, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival (PFS) using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 definition of progression as determined by the investigator.", 
            "safety_issue": "No", 
            "time_frame": "PFS is defined as the number of days from randomization to the earlier of death or disease progression for up to 36 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01685255"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety and tolerability of INCB024360 by adverse event assessment.", 
                "safety_issue": "Yes", 
                "time_frame": "Adverse events assessed every 2 weeks during cycle 1, then every 28 days thereafter until each subject's death or disease progression or for up to 36 months, whichever is longest."
            }, 
            {
                "measure": "Cancer Antigen (CA) 125 response rate, using Gynaecologic Cancer Intergroup (GCIG) criteria.", 
                "safety_issue": "No", 
                "time_frame": "CA 125 response rate defined as at least 50% reduction on study as compared to pretreatment sample; pre-treatment sample must be at least 2x ULN and response must be sustained for at least 28 days."
            }, 
            {
                "measure": "Duration of overall survival.", 
                "safety_issue": "No", 
                "time_frame": "Overall survival followed every 12 weeks until last date known to be alive, until subjects withdraw consent or up to 36 months, whichever is longest."
            }, 
            {
                "measure": "Progression-free survival using RECIST 1.1 definition of objective progression as determined by the central imaging laboratory.", 
                "safety_issue": "No", 
                "time_frame": "Progression free survival defined by central imaging lab using RECIST 1.1 assessed at 8 week intervals, retrospectively, until disease progression, death, subject withdraw of consent or up to 36 months, whichever is longest."
            }
        ], 
        "source": "Incyte Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Incyte Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}